GGrantIndex
← Leaderboards

Zachary Scott Morris

University Of Wisconsin-Madison

Google Scholar ↗PubMed ↗ORCID ↗
$7,480,359
Attributed
$9,785,666
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.3M · FY2017–25
$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$22,270,019 · 8

By mechanism

P01$14,684,208 · 4
U01$4,240,313 · 2
DP5$1,912,500 · 1
P50$1,432,998 · 1

Top collaborators

Most similar at University Of Wisconsin-Madison

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Tumor”

Research focus

TumorResponseRadiationIn VivoNeoplastic CellDoseSiteMolecular TargetImmunotherapyExternal Beam Radiation TherapyRadiation TherapyAnti-Tumor Immune ResponseImmunoregulationMalignant NeoplasmsTumor MicroenvironmentT Cell ResponseImmune Checkpoint InhibitorImmune ToleranceTumor-Infiltrating Immune CellsMediatingDisseminated Malignant NeoplasmRadioisotopesLocationImmunologics

Grant awards (33)

Project 1: Priming and propagating immunity against head and neck cancer using targeted radionuclide therapy$347,511
P50 · FY2025 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,361,658
P01 · FY2024 · CA
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition$361,468
P01 · FY2024 · CA · contact PI
Project 1: Priming and propagating immunity against head and neck cancer using targeted radionuclide therapy$353,107
P50 · FY2024 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$72,263
P01 · FY2024 · CA
Administrative-Core-001$72,263
P01 · FY2024 · CA
Administrative-Core-001$70,096
P01 · FY2024 · CA
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,452,679
P01 · FY2023 · CA
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition$384,278
P01 · FY2023 · CA · contact PI
Project 1: Priming and propagating immunity against head and neck cancer using targeted radionuclide therapy$364,957
P50 · FY2023 · CA · contact PI
Administrative-Core-001$74,545
P01 · FY2023 · CA
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$74,545
P01 · FY2023 · CA
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,453,778
P01 · FY2022 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2022 · CA · contact PI
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition$384,278
P01 · FY2022 · CA · contact PI
Project 1: Priming and propagating immunity against head and neck cancer using targeted radionuclide therapy$367,423
P50 · FY2022 · CA · contact PI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$165,219
U01 · FY2022 · CA · contact PI
Administrative-Core-001$70,033
P01 · FY2022 · CA
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$70,033
P01 · FY2022 · CA
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,508,454
P01 · FY2021 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2021 · CA · contact PI
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition$392,015
P01 · FY2021 · CA · contact PI
Combining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor Vaccination$382,500
DP5 · FY2021 · OD · contact PI
Gene Expression Analysis of Dog Natural Killer Cells Following Immunotherapy with Molecularly Targeted Radionuclide therapy or Inhaled IL-15$250,094
U01 · FY2021 · CA
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,490,943
P01 · FY2020 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2020 · CA · contact PI
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition$390,879
P01 · FY2020 · CA · contact PI
Combining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor Vaccination$382,500
DP5 · FY2020 · OD · contact PI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2019 · CA · contact PI
Combining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor Vaccination$382,500
DP5 · FY2019 · OD · contact PI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2018 · CA · contact PI
Combining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor Vaccination$382,500
DP5 · FY2018 · OD · contact PI
Combining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor Vaccination$382,500
DP5 · FY2017 · OD · contact PI